Skip to main content
SpringerLink
Log in

Anguidine potentiates cis-platinum in human brain tumor cells

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Summary

Anguidine pretreatment was previously shown to potentiate cis-platinum in Chinese hamster ovary cells by 100-fold, probably by enhancing cellular cis-platinum. uptake. Since both cis-platinum and anguidine have been reported to have clinical efficacy in human brain tumors, the present study was initiated to investigate whether anguidine's potentiation of cis-platinum was applicable to human brain tumor cells in culture. Using the colony formation assay, it was found that anguidine enhanced cis-platinum's cytotoxicity by ten-fold, producing a dose modification factor of 1.74. Alkaline elution analysis of cis-platinum-induced DNA crosslinks found that anguidine enhanced cross-linking by a factor of 1.55, 1.76, 1.63, and 1.48 at 0, 6, 24, and 48 hr, respectively, after cis-platinum treatment. This enhancement of cross-linking is evidence for anguidine increasing cis-platinum uptake. Thus, anguidine enhances cis-platinum-induced DNA cross-linking and subsequent cytotoxicity in human brain tumor cells, and may be clinically useful in combination with cis-platinum in those tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Edwards MS, Levin VA, Wilson CB: Brain tumor chemotherapy: An evaluation of agents in current use for phase II and III trials. Cancer Treat Rep 64:1179–1205, 1980.

    Google Scholar 

  2. Jelsma R, Bucy PL: The treatment of glioblastoma multiforme of the brain. J Neurosurg 27:388–400, 1967.

    Google Scholar 

  3. Walker MD, Green SB, Byar DP et al: Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. The New Engl Jour Med 23:1323–1329, 1980.

    Google Scholar 

  4. Armentrout SA, Foltz E, Vermund H et al: Comparison of postoperative irradiation alone and in combination with BCNU (NSC-409962) in the management of malignant gliomas. Cancer Chemother Rep 58:841–844, 1974.

    Google Scholar 

  5. Weir B, Band P, Urtasun R et al: Radiotherapy and CCNU in the treatment of high-grade supratentorial astrocytomas. J Neurosurg 45:129–134, 1979.

    Google Scholar 

  6. Khan A, McCullough D, Borts F, Sinks LF: Update on use of cis-platinum in CNS malignancies. Proc Am Assoc Cancer Res 21:390, 1980.

    Google Scholar 

  7. Leventhal BG, Freeman A: Cis-diamminedichloroplatinum — A phase II study in pediatric malignancies. Proc Am Assoc Cancer Res 20:197, 1979.

    Google Scholar 

  8. Rozencweig M, Von Hoff DD, Slavik M, Muggia F: Cisdiamminedichloroplatinum: A new anticancer drug. Ann Intern Med 86:803–812, 1977.

    Google Scholar 

  9. Stewart DS, Leavens M, Maor M, Fenn L, LunaM, Bonura J, Caprioli R, Loo TL, Benjamin R: Human central nervous system distribution of cis-diamminedichloroplatinum and use as a radiosensitizer in malignant brain tumors. Cancer Res 42:2474–2479, 1982.

    Google Scholar 

  10. Vich NA, Khandekar JB, Blaner DD: Chemotherapy of brain tumors. The ‘blood-brain barrier’ is not a factor. Arch Neurol 34:523–526, 1977.

    Google Scholar 

  11. Hromas R, Meyn R, Jenkins S, Barlogie B: Anguidine enhances cis-platinum-induced DNA cross-links in Chinese Hamster Ovary cells. Proc Am Assoc Cancer Res 25:370, 1984.

    Google Scholar 

  12. Hromas RA, Barlogie B, Swartzendruber D, Drewinko B: Potentiation of DNA-reactive antineoplastic agents and protection against S-phase-specific agents by anguidine in Chinese hamster ovary cells. Cancer Res 43:3070–3073, 1983.

    Google Scholar 

  13. Murphy WK, Burgess MS, Valdevieso M, Livingston RB, Bodey GP, Freireich EJ: Phase I clinical evaluation of anguidine. Cancer Treat Rep 62:1497–1502, 1978.

    Google Scholar 

  14. Yap MY, Murphy WK, Distefano A, Blumenschein GR, Bodey GP: Phase II study of anguidine in advanced breast cancer. Cancer Treat Rep 63:789–791, 1979.

    Google Scholar 

  15. Thigpen JT, Vaughn C, Stuckey WJ: Phase II trial of anguidine in patients with sarcomas unresponsive to prior chemotherapy: A Southwest Oncology Group study. Cancer Treat Rep 65:881–882, 1981.

    Google Scholar 

  16. Goodwin W, Stephens R, McCracken JD, Groppe C: Therapy for advanced colorectal cancer with a combination of 5-FU and anguidine: A Southwest Oncology Group study. Cancer Treat Rep 65:359, 1981.

    Google Scholar 

  17. Goodwin JW, Bottomley RH, Vaughn CB, Frank J, Pugh RP: Phase II evaluation of anguidine in central nervous system tumors: A Southwest Oncology Group study. Cancer Treat Rep 67:285–286, 1983.

    Google Scholar 

  18. Yung W-KA, Shapiro JR, Shapiro WR: Heterogenous chemosensitivities of subpopulations of human glioma cells in culture. Cancer Res 42:992–998, 1982.

    Google Scholar 

  19. Puck TT, Marcus PI: A rapid method for viable cell titration and clone production with HeLa cells in tissue culture. Proc Natl Acad Sci USA 41:432–437, 1955.

    Google Scholar 

  20. Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE: Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 50:219–244, 1966.

    Google Scholar 

  21. Kohn KW, Grimek-Ewig RA: Alkaline elution analysis, a new approach to the study of DNA single strand interruption in cells. Cancer Res 33:1849–1853, 1973.

    Google Scholar 

  22. Kohn KW, Erickson LC, Ewig RAG, Friedman LA: Fractionation of DNA from mammalian cells by alkaline elution. Biochemistry 15:4629–4637, 1976.

    Google Scholar 

  23. Kohn KW, Ewig RAG, Erickson LC, Zwelling LA: Measurement of strand breaks and cross-links in DNA by alkaline elution. In: Freidberg E, Hanowalat P (eds) DNA repair: A Laboratory Manual of Research Procedures, Marcel Dekker, New York, 1981, pp 379–401.

    Google Scholar 

  24. Meyn RE, Jenkins SF, Thompson LH: Defective removal of DNA cross-links in a repair-deficient mutant of Chinese hamster cells. Cancer Res 42:3106–3110, 1982.

    Google Scholar 

  25. Erickson LC, Zwelling LA, Ducore JM, Sharkey NA, Khon KW: Differential cytotoxicity and DNA cross-linking in normal and transformed human fibroblasts treated with cisdiamminedichloroplatinum II. Cancer Res 41:2791–2794, 1984.

    Google Scholar 

  26. Ducore JM, Erickson LC, Zwelling LA, Laurent G, Kohn KW: Comparative studies of DNA cross-linking and cytotoxicity in Burkitt's lymphoma cell lines treated with cis-diamminedichloroplatinum II and L-phenylalanine mustard. Cancer Res 42:897–902, 1982.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, The University of Texas System Cancer Center, MD Anderson Hospital and Tumor Institute, Houston, Texas

    Robert A Hromas

  2. Department of Neurology, The University of Texas System Cancer Center, MD Anderson Hospital and Tumor Institute, Houston, Texas

    WK Alfred Yung

Authors
  1. Robert A Hromas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. WK Alfred Yung
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hromas, R.A., Yung, W.A. Anguidine potentiates cis-platinum in human brain tumor cells. J Neuro-Oncol 3, 343–348 (1986). https://doi.org/10.1007/BF00165584

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00165584

Keywords

Search

Navigation